Statin Interventions in Prostate Cancer Management

Statins, inhibitors of HMG-CoA reductase, have emerged as promising adjuncts in prostate cancer management by disrupting cholesterol biosynthesis and related signalling networks. Laboratory studies indicate that statins induce cell cycle arrest, promote apoptosis and impair intratumoral androgen synthesis in both hormone-sensitive and castration-resistant models. Observational cohorts and pilot trials further suggest that statin use may lower the incidence of advanced disease, delay biochemical recurrence and enhance overall survival, particularly when combined with androgen-deprivation or next-generation antiandrogens. Mechanistic research implicates mTOR pathway modulation, reduction of androgen receptor levels and interference with lipid raft formation as key effects. Given their established safety profile and global accessibility, statins represent a viable repurposing opportunity to improve outcomes and overcome resistance in diverse prostate cancer populations.

Research from Nature Portfolio

A foundational meta-analysis of definitive treatment outcomes found that statin users experienced reduced risk of biochemical recurrence and lower prostate cancer-specific mortality, with radiotherapy patients benefiting most substantially. A parallel meta-analysis of LDL-lowering interventions reported no significant effect on overall prostate cancer incidence but observed a modest association with decreased risk of advanced and high-grade tumours, supporting the concept that cholesterol reduction may impede progression to aggressive disease.

Statin Interventions in Prostate Cancer Management publication trend

The graph below shows the total number of articles in statin interventions in prostate cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: The enzyme catalysing the rate-limiting step in cholesterol biosynthesis, inhibited by statins.

Mevalonate pathway: A metabolic cascade that produces cholesterol and isoprenoids essential for cell membrane integrity and signalling.

Castration-resistant prostate cancer (CRPC): A stage of prostate cancer that progresses despite suppression of gonadal androgens.

Biochemical recurrence (BCR): An increase in prostate-specific antigen following definitive therapy, signalling potential tumour relapse.

References

1. Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition. Nutrients (2023).
2. Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer. International Journal of Molecular Sciences (2023).
3. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Scientific Reports (2016).
4. LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. Scientific Reports (2016).
5. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer and Prostatic Diseases (2020).
6. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget (2018).